文献速递血栓与止血

癌症相关静脉血栓栓塞症停用抗凝治疗后复发的预测因素:一项多中心队列研究

Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study.
PubMed 文献 · J Thromb Haemost · 2023-04-15

本研究为RIETE国际多中心前瞻性队列分析,纳入14318例癌症相关VTE患者中3414例完成至少3个月全程抗凝后停药者,随访1年累积复发率为10.2%(95%CI 9.1-11.5),并识别出慢性肾病、特定肿瘤类型、下腔静脉滤器、血栓后综合征及残余肺动脉血栓阻塞等复发预测因素,而VTE前2个月内手术与复发风险降低相关。

要点

  • 癌症相关VTE停抗凝后1年复发累积发生率为10.2%(95%CI 9.1-11.5)。
  • 胰腺/胆道/原发不明肿瘤复发风险最高(sHR 6.86,95%CI 1.89-24.85)。
  • VTE前2个月内手术与复发风险降低相关(sHR 0.60,95%CI 0.40-0.92)。

核心结论

  • 癌症相关VTE停用抗凝治疗1年后约10%患者出现复发。
  • 停用抗凝治疗似乎安全,主要见于手术相关VTE。

研究设计与样本

  • 本研究为RIETE国际多中心前瞻性队列研究的分析。
  • 纳入VTE时存在活动性癌症且完成至少3个月全程抗凝后停药的患者。
  • 在14318例癌症相关VTE患者中,3414例接受了至少3个月的限时抗凝。
  • 分析采用Fine和Gray模型,以死亡为竞争风险,并用链式方程对缺失数据进行多重插补。

主要发现

  • 1年复发性VTE累积发生函数为10.2%(95%CI 9.1-11.5)。
  • 肾小球滤过率每降低10 mL/min,慢性肾病与复发相关(sHR 1.08,95%CI 1.02-1.14)。
  • 肺癌、脑癌、胃癌、食管癌、肝癌或卵巢癌较口咽癌、喉癌或黑色素瘤复发风险更高(sHR 3.56,95%CI 1.07-11.80)。
  • 胰腺癌、胆道癌或原发不明癌较口咽癌、喉癌或黑色素瘤复发风险更高(sHR 6.86,95%CI 1.89-24.85)。
  • 下腔静脉滤器(sHR 3.16,95%CI 1.75-5.71)、血栓后综合征(sHR 2.09,95%CI 1.06-4.15)及残余肺动脉血栓阻塞(sHR 2.58,95%CI 1.38-4.82)为复发预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on recurrence after the end of anticoagulation for a first event of cancer-associated venous thromboembolism (VTE) are scarce. OBJECTIVES: Our aim was to assess predictors of VTE recurrence during a 1-year follow-up period. METHODS: This study is an analysis of RIETE, an international, multicenter, prospective cohort study of patients diagnosed with VTE. Patients had to have active cancer at the time of VTE and to have withdrawn from anticoagulation after 3 months of full treatment. Analyses were performed using Fine and Gray models, with death as a competing risk, and multiple imputation of missing data was performed by chained equations. RESULTS: Among 14 318 patients with cancer-associated VTE, 3414 had undergone time-limited anticoagulation for at least 3 months. The cumulative incidence function for recurrent VTE was 10.2% (95% CI, 9.1-11.5) at 1 year. Chronic kidney disease (a subhazard ratio [sHR] of 1.08 for 10-mL/min decrease in glomerular filtration rate; 95% CI, 1.02-1.14); cancer of the lung, brain, stomach, esophagus, liver, or ovary (sHR, 3.56; 95% CI, 1.07-11.80; compared with cancer of the oropharynx, larynx, or melanoma); cancer of the pancreas, the biliary tract, or of unknown origin (sHR, 6.86; 95% CI, 1.89-24.85); inferior vena cava filter (sHR, 3.16; 95% CI, 1.75-5.71); postthrombotic syndrome (sHR, 2.09; 95% CI, 1.06-4.15); and residual pulmonary thrombotic obstruction (sHR, 2.58; 95% CI, 1.38-4.82) were predictive of recurrence. Surgery during the 2 months before VTE was predictive of absence of recurrence (sHR, 0.60; 95% CI, 0.40-0.92). CONCLUSION: One year after anticoagulant cessation for cancer-associated VTE, approximately 10% of patients experienced recurrence. Discontinuing anticoagulant therapy seems safe, mainly in surgery-associated VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lapébie FX, Bura-Rivière A, Espitia O, et al. Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study. J Thromb Haemost. 2023. PMID: 37068594. doi:10.1016/j.jtha.2023.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。